

# Drug-Induced Liver Disease

Richard A. Wright, M.D.

Professor and Chief

Division of Gastroenterology/Hepatology

Department of Medicine

University of Louisville

Louisville, Kentucky


# Drug-Induced Liver Disease

- Importance, epidemiology
- Possible mechanisms of hepatotoxicity
- Clinical presentation in selected hepatotoxic drugs
- Summary


# Importance of Drug-Induced Liver Disease

- Prognosis may be worse than for viral hepatitis
- Responsible for 3% to 10% of all adverse drug reactions; frequency appears to be increasing
- Drugs and toxins responsible for 1/3 of cases of fulminant hepatic failure
- Drug injury can mimic all forms of liver disease

# The Hepatic Portal Circulation




# Zones of the Liver



# Adverse Drug Reactions in Patients with Preexisting Liver Disease

- Risk of drug-induced liver injury generally the same in patients with or without preexisting liver disease
- Important exceptions: methotrexate and certain other antineoplastic agents
- Antibiotics metabolized primarily by the liver (sulfonamides and chloramphenicol) should be avoided because they can inhibit P450s that biotransform other drugs, while tetracyclines can be directly hepatotoxic

# Risk Factors for Drug-Induced Liver Disease




*Zimmerman, Hepatotoxicity 1978;3-10*

*Farrell. Drug-Induced Liver Disease 1994;85-99*




# General Mechanisms of Drug-Induced Injury










# Mechanism of Metabolite-Related Direct Hepatocellular Necrosis



# Cytochrome P450 Enzyme System and Drug Metabolism

- Cytochrome P450 – Class of MFO's
- Arabic numeral – family
  - >36% homologous amino acid sequence
- Capital letter – subfamily
  - >70% homologous amino acid sequence
- Arabic numeral – individual gene
  - eg, P4501A2
- Major liver P450s: 1A2, 2C9, 2D6, 2E1, and 3A4

MFOs = mixed function oxidases



Liver sample

TABLE II  
Contents of Liver Microsomal P450 Enzymes<sup>a</sup> in Japanese and Caucasian Populations<sup>24</sup>

		P450								Total P450 (immunochem- ical sum)
	Total P450 (spectral)	1A2	2A6	2B6	2C	2D6	2E1	3A4		
n		pmole P450/mg protein (% of total P450)								
Total	72	309±175 (100±57)	37±24 (13±7)	13±13 (4.0±4.1)	0.68±1.4 (0.15±0.26)	55±28 (20±8)	4.5±2.9 (1.7±1.2)	20±13 (6.6±3.1)	87±53 (29±10)	217±107 (73±17)
Japanese	40	233±102 (100±44)	26±20 (12±7)	6.5±7.3 (2.8±3.2)	0.14±0.62 (0.03±0.12)	46±23 (21±9)	3.0±1.9 (1.4±1.2)	15±9 (6.4±3.1)	72±44 (30±11)	168±80 (74±18)
Caucasian	32	406±199 (100±49)	50±22 (14±6)	21±14 (5.6±4.7)	1.4±1.8 (0.29±0.32)	68±29 (18±7)	6.4±2.8 (1.9±1.2)	26±14 (6.9±3.1)	106±58 (27±10)	277±106 (73±16)

<sup>a</sup>Total P450 contents in liver microsomes were determined spectrally<sup>25</sup> and individual forms of P450 were assayed immunochemically. All values are the means and standard deviations. Shown in parentheses are relative contents (% of total P450) of individual P450 forms.

# Characteristics of Human P450 Enzymes

P450	Chromosome location <sup>22</sup>	Known inducers	Approx. % total hepatic P450	Extent of variability in level, fold	Poly-morphism	Noninvasive markers
1A1	15q22-qter	TCDD	<1	~100	+	
1A2	15q22-qter	Smoking, charred food	12	40	(+)	Caffeine
1B	2	TCDD	<1			
2A6	19q13.1-13.2		4	30	+	Coumarin
2A7	19q13.1-13.2		?	?		
2B6	19q12-13.2		<1	50		
2C8	10q24.1-24.3					
2C9	10q24.1-24.3	Barbiturates, rifampicin	20 (total 2C)	25 (total 2C)	(+)	Hexobarbital, tolbutamide, warfarin
2C10 <sup>a</sup>	10q24.1-24.3					
2C17 <sup>a</sup>	10q24.1-24.3					
2C18	10q24.1-24.3					
2C19	10q24.1-24.3	Barbiturates, rifampicin		~100	+	(S)-Mephenytoin
2D6	22q13.1		4	>1000	+	Debrisoquine, dextromethorphan
2E1	10	Ethanol, isoniazid	6	20	(+)	Chlorzoxazone, caffeine
2F1	19		?	?		
3A4	7q22.1	Barbiturates, rifampicin, dexamethasone	28	20		Nifedipine, lidocaine, erythromycin, midazolam, dapsone, 6 $\beta$ -hydroxy-cortisol



# Chronic Ethanol Use Increases Sensitivity of Liver to Hepatotoxins

- Anesthetic agents
- Acetaminophen
- Isoniazid
- Cocaine
- Vitamin A
- Aflatoxins
- Methotrexate
- Carbon Tetrachloride

# Household Products that May Be Hepatotoxic

<i>Product</i>	<i>Chemical Toxin</i>
Moth balls	Chlorobenzene
Paint removers	Trichloroethane
Pesticides	Arsenic, paraquat, chloredacone
Toilet bowl block	Chlorobenzene
Antifreeze	Chlorobenzene

*Zimmerman. Hepatotoxicity 1978;319-332*



# Botanical Hepatotoxins

## *Toxin*

Poison mushrooms  
(*Amanita phalloides*)

Aflatoxin

Akee fruit (hypoglycin A)

Pyrrolizidine alkaloids  
(eg, from comfrey or  
Senecio varieties)

## *Hepatic Lesion*

Acute necrosis, fulminant hepatic failure

Acute necrosis, carcinoma

Microvesicular steatosis (Jamaican vomiting  
sickness)

Acute/chronic veno-occlusive disease, cirrhosis

*Bartoloni St. Omer et al. Hepatogastroenterology 1985;32:229-231*

*Zimmerman. Hepatotoxicity 1978;220-257, 319-332*

*Tanaka et al. N Engl J Med 1976;295:461-467*

*Farrell. Drug-Induced Liver Disease 1994:511-549*



# Botanical Hepatotoxins (cont'd)

## *Toxin*

## *Hepatic Lesion*

Chaparral

Acute hepatitis, necrosis

Germander

Acute hepatitis, necrosis

Chinese herbal remedies

Acute hepatitis, necrosis

(eg, Jin Bu Huan)

*Gordon et al. JAMA 1995;273:489-490*

*Larrey et al. Ann Intern Med 1992;117:129-132*

*Woolf et al. Ann Intern Med 1994;121:729-735*


**HERB MEDICINE**  
**BLACK PEPPER**

**FLATULENCE LAXATIVE**  
**WEIGHT REDUCING**  
**ANTI HYPERTENSIVE**  
**STOMACH INDIGESTION**  
**& ANTI HISTAMINE**





University of Louisville




University of Louisville






# Vitamin A Hepatotoxicity

- Daily intake >10,000 U
- Most common features: abnormal lab tests (63%) and hepatomegaly (47%)
- Hepatocellular injury/fibrosis
- Diagnosis by blood vitamin A levels/liver biopsy
- Duration is important
- Potentiated by chronic ethanol use
- Avoid alcohol







# Hepatotoxicity from Oral Contraceptives and Anabolic Steroids

<i>Lesion</i>	<i>Oral Contraceptives</i>	<i>C-17 alkylated anabolic steroids</i>
Cholestasis	+	+
Nodular regenerative hyperplasia	±	+
Peliosis hepatis	+	++
Hepatic vein thrombosis	+	-
Hepatic adenoma	++	+
Hepatocellular carcinoma	+	++
Angiosarcoma	-	+

*Zimmerman, Maddrey. In: Diseases of the Liver 1993:707-783*

*Chu, Farrell. J Gastroenterol Hepatol 1993;8:390-393*

*See et al. Liver 1992;12:73-79*


# Isoniazid (INH)-Induced Liver Injury

- Minor elevations in ALT:
  - Observed in 10% to 20% of patients
  - Within 2 months of starting treatment
  - Most resolve without stopping INH
- Severe liver injury with jaundice:
  - 1% of treated persons
  - 2% in persons >50 years of age
  - Women at increased risk
- Fulminant hepatic failure:
  - 10% of persons who develop jaundice
  - Continued treatment during prodrome increases hepatocyte necrosis
  - Resolution in nonfatal cases

ALT=alanine aminotransferase

*Black et al. Gastroenterology 1975;69:289-302*

*Farrell. Drug-Induced Liver Disease 1994:247-299*



# Hepatotoxicity from Psychotropic Drugs


<i>Class</i>	<i>Type of Injury</i>	<i>Frequency</i>	<i>Severity</i>
Phenothiazines (Chlorpromazine)	Cholestatic or mixed	1%	May be severe
Thioxanthenes (Chlorprothixene)	Cholestatic or mixed	Rare	Rarely severe
Butyrophenones (Haloperidol)	Cholestatic or mixed	<.02%	Rarely severe
Minor tranquilizers (Benzodiazepines)	Cholestatic or mixed	Rare	Rarely severe



*Zimmerman, Maddrey. In: Diseases of the Liver 1993:707-783*

*Rarrell. Drug-Induced Liver Disease 1994:319-369*



# Possible Mechanisms of Chlorpromazine Cholestasis






# Hepatotoxicity from Anticonvulsants

- Phenytoin, barbiturates, carbamazepine, and valproic acid can be hepatotoxic
- Rare, idiosyncratic, non-dose-related reactions
  - Incidence is 1 in 10,000 – 30,000 in adults
- Hypersensitivity features are common
- Approximately 10%-40% of clinically apparent reactions are fatal

# Mechanism of Phenytoin Toxicity








# Amidarone Hepatotoxicity

- Drug Effect
  - Phospholipidosis – multilamellar inclusion bodies due to drug-lipid complexes in lysosomes and inhibition of phospholipase
- Drug Toxicity
  - Elevated AST/ALT levels
  - Pseudoalcoholic liver disease in 1% to 3%
  - Granulomatous liver injury
  - Fibrosis or cirrhosis
- Cumulative Effect
  - Drug remains in the liver for up to 1 year after discontinuation





# Cocaine Hepatotoxicity

- Severe hepatic necrosis usually seen in association with heat-stroke-like syndrome (hyperpyrexia, acute renal failure, DIC, rhabdomyosis, shock)
- Mortality up to 44%
- ALT>400 IU/L and jaundice in those with severe injury
- Possible mechanism is P450-mediated reactive metabolites with depletion of glutathione and/or lipid peroxidation

DIC=Disseminated intravascular coagulation

*Silva et al. J Hepatol 1991;12:312-315*

*Wanless et al. Gastroenterology 1990;98:497-501*

*Perino et al. Gastroenterology 1987;93:176-180*

*Kanel et al. Hepatology 1990;11:646-651*

# Halothane-Induced Hepatic Injury

- “Halothane hepatitis” rare but severe
- May occur days or weeks postoperatively
- Injury more common with halothane than with other haloalkanes
- Reexposure increases risk markedly, suggesting allergic reaction
- Obesity and female sex are predisposing factors

*Farrell. Drug-Induced Liver Disease 1994;61:81-389-412*


*Martin et al Hepatology 1993;18:858-863*

*Knight et al. J Pharmaceol Exper Therp 1994;270:1325-1333*

# Acetaminophen Hepatotoxicity

- Acetaminophen hepatotoxic in large doses and often used to commit suicide
- Acetaminophen metabolism creates toxic metabolites that cause zone 3 necrosis when present at levels exceeding the liver's detoxification capacity
- Evolution of injury in three phases
  - Phase I – acute GI symptoms (1-4 hours)
  - Phase II – latent (1-3 days)
  - Phase III – liver damage/failure (3-10 days)
- About 15% of patients with overt liver injury die


# Glutathione: Role in Acetaminophen-Induced Liver Disease



Fontana, Watkins. *Gastroenterol Clin North Am* In Press

Watkins. *Semin Liver Dis* 1990;10:235-250


# Potential of Acetaminophen Hepatotoxicity





University of Louisville

# Treatment of Acetaminophen Hepatotoxicity



## IV N Acetylcysteine for Acetaminophen Overdose

- 15 minutes preparation and delivery  
AFTER weight is sent to pharmacy
- 150 mg/ kg over 60 minutes
- 50 mg/kg over next 4 hours
- 100 mg/ kg over 16 hours

# The Good Stuff

- Pentoxifylline (Trental) 400 mg po tid
- N Acetylcysteine (mucomyst) 20% in cola diluted to 5% (140 mg/kg then 70 mg/kg q4h)
- Zinc sulfate 220 mg po tid
- SAMe ????

# Acetaminophen Use and the Alcoholic Patient

- Social drinkers may be at risk
- Ethanol makes even “safe” therapeutic doses of acetaminophen potentially hepatotoxic
- High levels of AST (3,000 – 48,000 IU) in >90% of patients
- Patients without acute disease have suffered subclinical toxicity with early evolution to cirrhosis



# Troglitazone (Rezulin)

- Idiosyncratic hepatocellular injury
- Deaths and liver transplants reported
- Nausea, vomiting, anorexia, malaise, pruritus, jaundice
- Onset 2 weeks to 7 months
- Monitor ALT, AST every month for 6 months and every 2 months for remainder of first year. If ALT >2x normal, discontinue

# Trovafloxacin (Trovan)

- 14 cases of acute liver failure
  - 4 liver transplant, 5 others died of liver disease
- Idiosyncratic hepatocellular injury
- 6/99 FDA issued public health advisory
  - Trovafloxacin Guidelines
    - Life-threatening infection
    - Inpatient (IV) only initially (PO as outpatient afterwards)
    - 14 day therapy maximum
    - Discontinue if fatigue, anorexia, abdominal pain, nausea, vomiting, dark urine, jaundice

# Ketek (telithromycin)

- 4 Deaths (hepatic failure)
- 12 Cases of Acute Liver Failure
- 23 Cases of reported hepatotoxicity

*FDA June 29, 2006*

# Ezetimibe (Zetia)

- Cholestatic
- Hepatocellular
- Autoimmune (positive SMA and steroid response)

*Clin Gastro Hep 2006;4:908-911*

# Duloxetine (Cymbalta)

- Case Report of fulminant hepatic failure leading to death in 6 weeks
- Pathology-Centrolobular dropout with ballooning degeneration and mixed inflammatory infiltrate



# NSAID Hepatic Injury

- Nonuniform
- Drugs differ
- Incidence
- Character and gravity
- Mechanism

# NSAID Frequency of Hepatic Injury

## *Very Low*

Ibuprofen

Indomethacin

Naproxen

Oxaprozin

Piroxicam

Cox-2 Inhibitors


## *Low*

Diclofenac

Phenylbutazone

Pirprofen

Sulindac



# Summary of Drug-Induced Liver Disease


- Numerous agents have hepatotoxic potential
- Liver injury
  - Direct or indirect
  - Predictable or idiosyncratic
  - Genetics may predispose
- P450s induced by drugs or by other substances taken concomitantly
- Awareness of causes and protentiating role of ethanol should help prevent iatrogenic hepatotoxicity or limit the injury

# Drug-Induced Liver Disease





# Direct and Hypersensitivity Hepatotoxicity



# Prevention of Drug-Induced Liver Disease: Iatrogenic Risk Factors

- Age-dependent injury, such as
  - Isoniazid (INH) and age >35 years
  - Valproic acid and age <12 years
- Reye's syndrome and salicylates
- Prior reaction to a halogenated anesthetic

# Intrinsic and Idiosyncratic Reactions to Hepatotoxins

Characteristic	Intrinsic	Idiosyncratic
Incidence	High	Low
Predictability	Yes	No
Dose-dependence	Yes	No
Reproducibility	Yes	No
Host dependence	No	Yes
Morphologic expressions	Usually necrosis or steatosis	Broad spectrum
Mechanisms of injury	Biochemical	Biochemical and/or immunologic
Examples of hepatotoxins	Acetaminophen	Valproic acid Phenytoin Halothane Sulfonamides Isoniazid

*Zimmerman. Hepatotoxicity 1978:91-121*

*Zimmerman, Maddrey. In: Diseases of the Liver 1993;707-783*

*Waters, Riely. In: Bockus Gastroenterology 1995:2158-2189*


University of Louisville



# Clinicopathologic Classification of Drug-Induced Liver Disease (cont'd)

Type	Features	Examples
Acute cholestasis	No hepatitis; minimal systemic symptoms; SAP > 2N Hepatitis; systemic symptoms; ↑ ALT and SAP; bile duct injury (with chlorpromazine)	Oral contraceptives, anabolic steroids Chlorpromazine, erythromycin
Chronic cholestasis	Cholestasis for > 3 months; fibrosis	Chlorpromazine, amitriptyline
Chronic parenchymal liver disease	Abnormalities present for > 3 months	
Chronic active hepatitis	Necrosis, fibrosis, or cirrhosis; liver failure may occur	Methyldopa, nitrofurantoin
Fibrosis and cirrhosis only	Portal hypertension; liver tests often normal	Methotrexate; vitamin A





# Clinicopathologic Classification of Drug-Induced Liver Disease (cont'd)

Type	Features	Examples
Vascular disorders	Sinusoidal lesions; hepatomegaly Budd-Chiari Syndrome; portal vein lesions; hepatic arterial lesions	Oral contraceptives
Hepatic tumors		
Hemangioma	Asymptomatic	Oral contraceptives
Hepatocellular adenoma	Benign neoplasm of hepatocytes	Oral contraceptives
Hepatocellular carcinoma	Primary liver cancer	Oral contraceptives

# Drug-Induced Liver Disease


University of Louisville



# Clinicopathologic Classification of Drug-Induced Liver Disease

Type	Features	Examples
Altered liver tests without liver disease	None; ↑ GGT and SAP Jaundice (rare); ↑ bilirubin	Phenytoin, warfarin, rifampin
Acute hepatocellular necrosis	Hepatocellular necrosis with varying inflammation; ALT > 5N	Isoniazid, cloxacillin, halothane, acetaminophen, valproic acid
Fatty liver Acute fatty change	Usually microvesicular; typically diffuse; clinical features of hepatitis	Tetracycline, valproic acid, corticosteroids
Steatohepatitis	Resembles alcoholic hepatitis	Perhexiline, amiodarone
Granulomatous reactions	Granulomas, varying lobular hepatitis, cholestasis, or pericholangitis	Hydralazine, allopurinol, carbamazepine

# Possible Mechanisms of Hepatic Tumor Production by Sex Hormones





# Oral Contraceptives and Benign Hepatic Tumors

- Relatively rare in general
- Hepatic adenomas directly related to duration of contraceptive use, often regress when contraceptive discontinued, and rarely transform to hepatocellular carcinoma
- Focal nodular hyperplasia: a weak link
- May enlarge preexisting hemangiomas

*Klatskin. Gastroenterology 1977;73:386-394*

*Gyorffy et al. Ann Intern Med 1989;110:489-490*

*Ishak, Rabin. Med Clin North Am 1975;59:995-1013*

*Conter, Longmire. Ann Surg 1988;207:115-119*

*Zimmerman, Maddrey. In: Diseases of the Liver 1993: 707-783*

# Types of Idiosyncratic Injury

Type	Exposure	Clinical features	Rechallenge
Hypersensitivity	Weeks	Systemic response, rash, fever, eosinophilia	Prompt
Aberrant metabolism	Months	Liver only	Delayed
Mixed	Variable	Both	Prompt

TABLE III

Useful Markers and Inhibitors of Major Human Liver P450 Enzymes

P450	Marker substrate	Inhibitors
1A2	Phenacetin <i>O</i> -deethylation 7-Ethoxyresorufin <i>O</i> -deethylation	7,8-Benzoflavone Fluvoxamine Furafylline <sup>a</sup>
2A6	Coumarin 7-hydroxylation	Diethyldithiocarbamate
2C9	Tolbutamide (methyl) hydroxylation	Sulfaphenazole
2C19	( <i>S</i> )-Mephenytoin 4-hydroxylation	
2D6	Bufuralol 1-hydroxylation Debrisoquine 4-hydroxylation	Quinidine Ajmalicine
2E1	Chlorzoxazone 6-hydroxylation	4-Methylpyrazole Diethyldithiocarbamate
3A4	Nifedipine oxidation	Gestodene Troleandomycin
4A11	Lauric acid 12-hydroxylation	
7	Cholesterol 7 $\alpha$ -hydroxylation	

<sup>a</sup>This has been reported to be a very selective inhibitor of human P450 1A2<sup>30-32</sup> but work in this laboratory indicates considerably less inhibition or specificity.<sup>33</sup>

## 1A2 Clinically Significant Drug Interactions

Substrate	Inhibitor, Inducer, Competing Substrate	Management	Alternatives
Chlordiazepoxide Diazepam Others?	Smoking, PAH (ind)	Less drowsiness in smokers; may require higher dosages.	
Clozapine Haloperidol	Fluvoxamine (inh)	Avoid combination; resulted in markedly increased serum conc with symptoms of EPS.	Fluoxetine Paroxetine Sertraline
Miscellaneous Tacrine	Smoking, PAH (ind)	Mean plasma conc 1/3 less in smokers; may require higher dosages.	
	Cimetidine (inh)	Decreases clearance 30%; monitor for anticholinergic side effects.	Famotidine Nizatidine Ranitidine
	Enoxacin (inh) Ciprofloxacin (inh) Norfloxacin (inh)	Theoretical.	Lomefloxacin Ofloxacin Sparfloxacin